e-Drug3D

1639

M NELARABINE


INN
NELARABINE

(is an active metabolite)

cas 72490-81-4
CLASS

ANTINEOPLASTIC
TREATMENT OF PATIENTS WITH T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA AND T-CELL LYMPHOBLASTIC LYMPHOMA
FOR INCORPORATION INTO DE OXYRIBONUCLEIC ACID (DNA)

ROUTE (list)

-

ATC code

L01BB07

PK parameters

Cmax 86.5 MICROMOLAR
VD 80 LITER
Cl 16.9 LITER / HOUR
PPB 25 PERCENT
t1/2 3.2 HOUR

Target

TARGET DNA

DrugCentral

Unknown

Download SDF file 6H-Purin-6-one, 2-amino-1,9-dihydro-9-[5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-beta-D-arabinofuranosyl]-

Formula:
C10H16N5O14P3

Calculated chemical properties:

MW 519.16
NB_atoms 32
XLogP -4.45
PSA 285.943
NB_HD 5
NB_HA 19
fsp3 0.50
Lipinski(0=no;1=yes) 0

FDA
-

Other links:

PubChem
ChemicalProbes

U.S. repository of Clinical Trials

VigiAccess
SIDER side effects

ChemSynthesis
Patent@SureChEMBL

e-Drug3D

940

NELARABINE


INN
NELARABINE

(has an active metabolite)

cas 121032-29-9
CLASS

ANTINEOPLASTIC
PRODRUG
TREATMENT OF PATIENTS WITH T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA AND T-CELL LYMPHOBLASTIC LYMPHOMA

ROUTE (list)

INTRAVENOUS

ATC code

L01BB07

PK parameters

Cmax 16.8 MICROMOLAR
VD 318.5 LITER
Cl 315 LITER / HOUR
PPB 25 PERCENT
t1/2 0.3 HOUR

Solubility

SLIGHTLY SOLUBLE TO SOLUBLE IN WATER


Target

TARGET ADENOSINE DEAMINASE

DrugCentral

Unknown

Download SDF file (2R,3S,4S,5R)-2-(2-amino-6-methoxypurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol

Formula:
C11H15N5O5

Calculated chemical properties:

MW 297.28
NB_atoms 21
XLogP -1.97
PSA 142.218
NB_HD 5
NB_HA 10
fsp3 0.55
Lipinski(0=no;1=yes) 0

FDA
NDA 021877 (label) INN (NELARABINE) ARRANON (SANDOZ) APPROVAL= AP YEAR= 2005 NEWMOLECULARENTITY
NDA 215037 (pdf not found) INN (NELARABINE) NELARABINE (ZYDUS PHARMS) APPROVAL= AP YEAR= 2021
NDA 216934 (pdf not found) INN (NELARABINE) NELARABINE (DR REDDYS) APPROVAL= AP YEAR= 2022
NDA 214809 (pdf not found) INN (NELARABINE) NELARABINE (SHORLA) APPROVAL= AP YEAR= 2023
NDA 215057 (pdf not found) INN (NELARABINE) NELARABINE (NEXUS) APPROVAL= AP YEAR= 2023
NDA 216038 (pdf not found) INN (NELARABINE) NELARABINE (MEITHEAL) APPROVAL= AP YEAR= 2023
NDA 216346 (pdf not found) INN (NELARABINE) NELARABINE (AMNEAL) APPROVAL= AP YEAR= 2023
NDA 212605 (pdf not found) INN (NELARABINE) NELARABINE (GLAND) APPROVAL= AP YEAR= 2024
NDA 216510 (pdf not found) INN (NELARABINE) NELARABINE (XGEN PHARMS) APPROVAL= AP YEAR= 2024
NDA 216948 (pdf not found) INN (NELARABINE) NELARABINE (MSN) APPROVAL= AP YEAR= 2024
NDA 218554 (pdf not found) INN (NELARABINE) NELARABINE (ALEMBIC) APPROVAL= AP YEAR= 2024

Other links:

PubChem
ChemicalProbes

U.S. repository of Clinical Trials

VigiAccess
SIDER side effects

ChemSynthesis
Patent@SureChEMBL